Glaukos Corporation (GKOS)
| Market Cap | 9.77B +94.5% |
| Revenue (ttm) | 612.84M +41.5% |
| Net Income | -188.05M |
| EPS | -3.25 |
| Shares Out | 58.96M |
| PE Ratio | n/a |
| Forward PE | 1,406.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,196,008 |
| Open | 160.06 |
| Previous Close | 161.29 |
| Day's Range | 159.89 - 166.97 |
| 52-Week Range | 73.16 - 191.62 |
| Beta | 0.70 |
| Analysts | Strong Buy |
| Price Target | 198.69 (+19.92%) |
| Earnings Date | Oct 28, 2026 |
About GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ... [Read more]
Financial Performance
In 2025, Glaukos's revenue was $507.44 million, an increase of 32.33% compared to the previous year's $383.48 million. Losses were -$187.69 million, 28.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price target is $198.69, which is an increase of 19.92% from the latest price.
News
Glaukos announces Phase 4 trial of iDose TR met primary efficacy endpoint
Glaukos (GKOS) announced topline results from the Phase 4 prospective, randomized, controlled clinical trial evaluating iDose TR administered in conjunction with cataract surgery compared to cataract ...
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos announces exclusive license agreement with RevOpsis for RO-104
Glaukos (GKOS) announced an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macul...
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos says late-stage eye disease treatment shows lasting benefits after single dose
Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improvements in vision and corneal shape three years after a single treatment for keratoconus, a disease...
Glaukos reports ‘positive’ three-year Epioxa results
Glaukos (GKOS) announced positive topline results from a long-term Phase 3 extension study evaluating the durability, visual outcomes, and safety of Epioxa, the company’s groundbreaking epi-on corneal...
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos partners with Stephen Curry for keratoconus awareness campaign
Glaukos (GKOS) Corporation announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recogn...
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos price target raised to $210 from $190 at Jefferies
Jefferies raised the firm’s price target on Glaukos (GKOS) to $210 from $190 and keeps a Buy rating on the shares. The ophthalmology sector has been under pressure over the…
Glaukos Transcript: Wells Fargo 21st Annual Healthcare Conference
Epioxa's commercial launch is progressing, with payer access expanding and Photrexa sunset. iDose growth continues, though guidance is cautious due to seasonality and reimbursement uncertainty. The pipeline is robust, with new device launches and pivotal trial data expected in the next 12–18 months.
Glaukos price target raised to $202 from $193 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $202 from $193 and keeps a Buy rating on the shares as part of a broader research note updating the…
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di...
Glaukos price target raised to $225 from $188 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Glaukos (GKOS) to $225 from $188 and keeps a Buy rating on the shares. The firm is more optimistic on…
Glaukos Slides: Investor presentation
Glaukos has posted slides in relation to its latest quarterly earnings report, which was published on July 31, 2026.
Glaukos price target raised to $195 from $168 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Glaukos (GKOS) to $195 from $168 and keeps a Buy rating on the shares after a beat and raise Q2 report. Management…
Glaukos price target raised to $172 from $150 at UBS
UBS raised the firm’s price target on Glaukos (GKOS) to $172 from $150 and keeps a Neutral rating on the shares.
Glaukos price target raised to $193 from $164 at BTIG
BTIG raised the firm’s price target on Glaukos (GKOS) to $193 from $164 and keeps a Buy rating on the shares. The company delivered “above and beyond” Q2, with iDose…
Glaukos price target raised to $201 from $150 at Needham
Needham analyst David Saxon raised the firm’s price target on Glaukos (GKOS) to $201 from $150 and keeps a Buy rating on the shares after its better-than-expected Q2 results and…
Glaukos price target raised to $190 from $175 at Stifel
Stifel raised the firm’s price target on Glaukos (GKOS) to $190 from $175 and keeps a Buy rating on the shares.
Glaukos price target raised to $195 from $165 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Glaukos (GKOS) to $195 from $165 and keeps an Overweight rating on the shares. The firm notes Glaukos posted…
Glaukos price target raised to $188 from $175 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Glaukos (GKOS) to $188 from $175 and keeps a Buy rating on the shares.
Glaukos price target raised to $178 from $138 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised the firm’s price target on Glaukos (GKOS) to $178 from $138 and keeps an Overweight rating on the shares. The firm notes the company…